Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial

Summary

This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will receive individual psychotherapy sessions plus a 30 mg dose of psilocybin. Arm 2 subjects (n=40) will receive individual psychotherapy sessions and a 0.75 mg/kg dose of ketamine.

Timeline

Start

2025-06-12

Primary completion

2028-04

Completion

2028-04

Drugs

Indications